MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10549-018-4740-z

Медицинская библиотека · Breast cancer research and treatment · 2018

Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.

Park Soo Jin, Lee Moo Hyun, Kong Sun-Young, Song Mi Kyung, Joo Jungnam, Kwon Youngmee, Lee Eun-Gyeong, Han Jai Hong, Sim Sung Hoon, Jung So-Youn, Lee Seeyoun, Lee Keun Seok, Park In Hae, Lee Eun Sook

СтатьяПеревод в очереди

Аннотация

PURPOSE: We assessed the use of chemotherapy in breast cancer patients to investigate the factors that changed trends in chemotherapy following the adoption of the 21-gene expression assay in tumor genomic profiling.

METHODS

Our study used 2033 patients from the National Cancer Center in Korea diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (tumor size of 0.5 cm or larger and 0-3 node metastases) from 2010 to 2015. We analyzed use of the 21-gene expression assay, changes in frequency of adjuvant chemotherapy use, and clinicopathological factors related to adjuvant chemotherapy to assess the impact of the 21-gene expression assay.

RESULTS

Adjuvant chemotherapy use declined from 33.33% (2011) to 13.59% (2015) [relative risk (RR), 0.71; 95% CI 0.56-0.89; ptrend = 0.004] in patients with 21-gene expression assay data. Among patients without assay data, adjuvant chemotherapy use decreased from 76.79 to 40.17% between 2010 and 2015 (RR 0.87; 95% CI 0.84-0.91; ptrend < 0.001), especially for patients with node-negative/micrometastasis (RR 0.85; 95% CI 0.81-0.89; ptrend < 0.001). The frequency of adjuvant chemotherapy was significantly decreased after introduction of the 21-gene expression assay (p < 0.001). Tumor size (p < 0.001), progesterone receptor (PgR) status (p = 0.001), and proliferation index (Ki-67) levels (p < 0.001) were important factors for chemotherapy decision-making in node-negative/micrometastasis patients who did not undergo the assay.

CONCLUSIONS

For HR-positive, HER2-negative breast cancer patients with 0-1 node metastases, chemotherapy use declined significantly after the adoption of the 21-gene assay. PgR status and Ki-67 were useful for chemotherapy decision-making in cases without the 21-gene assay.

Для цитирования: Park Soo Jin, Lee Moo Hyun, Kong Sun-Young, Song Mi Kyung, Joo Jungnam, Kwon Youngmee, Lee Eun-Gyeong, Han Jai Hong, Sim Sung Hoon, Jung So-Youn, Lee Seeyoun, Lee Keun Seok, Park In Hae, Lee Eun Sook. Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.. Breast cancer research and treatment. 2018. DOI: 10.1007/s10549-018-4740-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.